A preprint abstract from medrxiv.org discusses the potential use of plasma endostatin as a biomarker for predicting acute kidney injury (AKI) and the need for renal replacement therapy (RRT) in the intensive care unit (ICU). The study, which included 4449 admissions to four ICUs, found that endostatin was associated with AKI, future AKI, future AKI stage 3, and RRT, independently of creatinine and cystatin C. In patients with low to mildly elevated creatinine, endostatin outperformed creatinine and cystatin C in predicting future AKI. However, endostatin was not associated with 30-day mortality. This research has not yet undergone peer review. [Extracted from the article]